The Roche’s ‘Avastin’ is domestically approved for the indication of cervical cancer
The indication of the targeted agent, ‘Avastin’, has domestically been approved.
Thus, Avastin (bevacizumab) is now able to jointly use either taxane-type (paclitaxel) and platinum-type (cisplatin) drugs or paclitaxel and topotecan targeting durable, recurrent and metastatic cervical cancer pati...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
